FOLFIRI regimen as second-/third-line chemotherapy in patients with advanced pancreatic adenocarcinoma refractory to gemcitabine and platinum salts: A retrospective series of 70 patients.

被引：0
|
作者：
Neuzillet, C.
Hentic, O.
Rousseau, B.
Rebours, V.
Bengrine-Lefevre, L.
Bonnetain, F.
Raymond, E.
Ruszniewski, P.
Louvet, C.
Hammel, P.
机构：
[1] Hop Beaujon, Clichy La Garenne, France
[2] Hop St Antoine, F-75571 Paris, France
[3] Ctr Georges Francois Leclerc, Dijon, France
[4] Beaujon Univ Hosp, Clichy, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.4132
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4132
引用
收藏
页数：1
相关论文
共 50 条
  • [1] FOLFIRI regimen as second-/third-line chemotherapy in patients with advanced pancreatic adenocarcinoma refractory to gemcitabine and platinum salts: A retrospective series of 70 patients.
    Neuzillet, C.
    Hentic, O.
    Rousseau, B.
    Rebours, V.
    Bengrine-Lefevre, L.
    Raymond, E. Ut
    Ruszniewski, P.
    Louvet, C.
    Hammel, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [2] Second- and third-line chemotherapy in patients with metastatic pancreatic adenocarcinoma: Feasibility and potential benefits in a retrospective series of 117 patients
    Bachet, J. -B.
    Mitry, E.
    Lievre, A.
    Lepere, C.
    Vaillant, J. -N.
    Declety, G.
    Parlier, H.
    Emile, J. -F.
    Julie, C.
    Rougier, P.
    GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 2009, 33 (10-11): : 1036 - 1044
  • [3] FOLFIRI regimen as second- and third-line chemotherapy for metastatic biliary tract or pancreatic cancer.
    Loioia, Fernanda Navarro
    Guedes Camandaroba, Marcos Pedro
    Oliveira Fernandes, Viviane Teodoro
    Rodrigues Pereira, Augusto Akikubo
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [4] Second- and third-line chemotherapy regimens in elderly Medicare stage IV colon cancer patients.
    Bikov, Kaloyan A.
    Mullins, C. Daniel
    Onukwugha, Ebere
    Seal, Brian S.
    Hanna, Nader
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [5] Capecitabine as Second- and Third-line Chemotherapy in the Treatment of Platinum-refractory Epithelial Ovarian Cancer
    Veljanoska, S.
    Klisarovska, V.
    Arsovski, O.
    Basevska, N.
    Stojkovski, I.
    Simonova, D.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S537 - S537
  • [6] The Prognostic Role of KRAS Mutation in Patients with Advanced NSCLC Treated with Second- or Third-line Chemotherapy
    Svaton, Martin
    Fiala, Ondrej
    Pesek, Milos
    Bortlicek, Zbynek
    Minarik, Marek
    Benesova, Lucie
    Topolcan, Ondrej
    ANTICANCER RESEARCH, 2016, 36 (03) : 1077 - 1082
  • [7] Pemetrexed as a Component of First-, Second- and Third-line Chemotherapy in Treating Patients with Metastatic Lung Adenocarcinoma
    Huang, Xin-En
    Tian, Guang-Yu
    Cao, Jie
    Xu, Xia
    Lu, Yan-Yan
    Wu, Xue-Yan
    Liu, Jin
    Shi, Lin
    Xiang, Jin
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2013, 14 (11) : 6663 - 6667
  • [8] A retrospective study of gemcitabine with nab-paclitaxel as third-line retreatment in advanced pancreatic adenocarcinoma
    McSweeney, T.
    Das, A.
    O'Mahony, A.
    O'Tighearnaigh, F.
    O'Byrne, L.
    Feely, M.
    Passmore, E.
    Keane, S.
    Lanigan, S.
    Fitzgerald, S.
    Browne, T.
    De Beer, V.
    Dean, A.
    ANNALS OF ONCOLOGY, 2023, 34 : S126 - S126
  • [9] The nab-paclitaxel/gemcitabine regimen for patients with refractory advanced pancreatic adenocarcinoma
    Palacio, Sofia
    Hosein, Peter J.
    Reis, Isildinha
    Akunyili, Ikechukwu I.
    Ernani, Vinicius
    Pollack, Terri
    Macintyre, Jessica
    Restrepo, Maria H.
    Merchan, Jaime R.
    Lima, Caio M. Rocha
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2018, 9 (01) : 135 - 139
  • [10] High-Dose Ifosfamide as Second- or Third-Line Chemotherapy in Refractory Bone and Soft Tissue Sarcoma Patients
    Lee, Soo Hyeon
    Chang, Myung Hee
    Baek, Kyung Kee
    Han, Boram
    Lim, Taekyu
    Lee, Jeeyun
    Park, Joon Oh
    ONCOLOGY, 2011, 80 (3-4) : 257 - 261
12345